Botulinum toxins are potent neurotoxins used in a variety of neurological disorders. Few pediatric reports have been published to date regarding the potential hazards of therapeutic use of botulinum toxins. We describe the case of a 10-year-old boy who developed systemic weakness following treatment of spasticity with botulinum toxin type B. The patient developed iatrogenic botulism with ptosis, facial diplegia, neck flexor and extensor weakness, and profound hypopharyngeal laxity with respiratory compromise from which he eventually recovered. Clinicians should be mindful of the risk for systemic botulism when using local injections of the neurotoxin.
Jankovic J.Dystonia: medical therapy and botulinum toxin. Adv Neurol.2004;94:275-286.
2.
Blitzer A.Botulinum toxin A and B: a comparative dosing study for spasmodic dysphonia . Otolaryngol Head Neck Surg.2005;133(6): 836-838.
3.
Dressler D., Eleopra R.Clinical use of non-A botulinum toxins: botulinum toxin type B. Neurotox Res. 2006;9(2-3):121-125.
4.
Jongerius PH , Rotteveel JJ, van Limbeek J., Gabreels Fjm, van Hulst K., van den Hoogen Fja.Botulinum toxin effect on salivary flow rate in children with cerebral palsy. Neurology.2004;63(8): 1371-1375.
5.
Lenaerts MEPharmacoprophylaxis of tension-type headache. Curr Pain Headache Rep. 2005;9(6):442-447.
6.
Schwerin A., Berweck S., Fietzek UM, Heinen F.Botulinum toxin B treatment in children with spastic movement disorders: a pilot study. Pediatr Neurol.2004;31(2):109-113.
7.
Scott ABBotulinum toxin injection into extraocular muscles as an alternative to strabismus surgery. J Pediatr Ophthalmol Strabismus. 1980;17(1):21-25.
8.
Silberstein S., Mathew N., Saper J., Jenkins S.; BOTOX Migraine Clinical Research Group. Botulinum toxin type A as a migraine preventive treatment. Headache . 2000;40(6):445-450.
9.
Arnon SS, Schechter R., Inglesby TV, et al. Botulinum toxin as a biological weapon: medical and public health management. JAMA.2001;285(8):1059-1070.
10.
Schantz EJ, Johnson EAProperties and use of botulinum toxin and other microbial neurotoxins in medicine . Microbiol Rev. 1992;56(1):80-99.
11.
Grumelli C. , Verderio C., Pozzi D., Rossetto O., Montecucco C., Matteoli M.Internalization and mechanism of action of clostridial toxins in neurons. Neurotoxicology.2005;26(5):761-767.
12.
Comella CL, Jankovic J., Shannon KM, et al. Comparison of botulinum toxin serotypes A and B for the treatment of cervical dystonia. Neurology. 2005;65(9):1423-1429.
13.
Beseler-Soto B., Sanchez-Palomares M., Santos-Serrano L., Landa-Rivera L., Sanantonio-Valdearcos F., Paricio-Talayero JMIatrogenic botulism: a complication to be taken into account in the treatment of child spasticity [in Spanish]. Rev Neurol.2003;37(5):444-446.
14.
Bhatia KP, Munchau A., Thompson PD, et al. Generalised muscular weakness after botulinum toxin injections for dystonia: a report of three cases. J Neurol Neurosurg Psychiatry. 1999; 67(1):90-93.
15.
Racette BA, Lopate G., Good L., Sagitto S., Perlmutter JSPtosis as a remote effect of therapeutic botulinum toxin B injection. Neurology. 2002;59(9):1445-1447.
16.
Tugnoli V., Eleopra R., Quatrale R., Capone JG, Sensi M., Gastaldo E.Botulism-like syndrome after botulinum toxin type A injections for focal hyperhidrosis . Br J Dermatol.2002;147(4):808-809.
17.
Goldstein EMSafety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol.2006;21(3):189-192.
18.
Rossi RP, Strax TE, Di Rocco A.Severe dysphagia after botulinum toxin B injection to the lower limbs and lumbar paraspinal muscles. Am J Phys Med Rehabil. 2006;85(12):1011-1013.
19.
Dressler D. , Hallett M.Immunological aspects of Botox, Dysport and Myobloc/NeuroBloc. Eur J Neurol.2006;13(suppl 1):11-15.
20.
Molenaers G. , Desloovere K., Fabry G., De Cock P.The effects of quantitative gait assessment and botulinum toxin A on musculoskeletal surgery in children with cerebral palsy. J Bone Joint Surg Am.2006;88(1):161-170.
